I keep reaching for my phone, and it’s not for scrolling.

While cloud services like ChatGPT and Gemini are the mainstream for AI, many users still prefer to run AI models locally due to reasons such as wanting to run AI without being restricted by usage ...

President Donald Trump speaks before signing an executive order on fraud in the Oval Office at the White House in Washington, D.C., on March 16, 2026, as Vice President JD Vance looks on. (Photo by ...

The company will continue to distribute library content, but will end production of first-run syndicated programming in a strategic shift. By Alex Weprin Senior Editor “NBCUniversal is making changes ...

Japanese Prime Minister Sanae Takaichi condemned Iran’s nuclear program in a carefully worded response that avoided commenting on whether Tokyo supported Washington’s strike on Tehran. “We are working ...

CHARLESTON — A nonprofit run by City Councilman Aaron Polkey, who was sworn in last month, is set to receive nearly $240,000 from the city for a homeless program. Polkey, president and CEO of Palmetto ...

Former Vice President Kamala Harris is said to be mulling another run for the White House, a race that would be her third attempt to become the nation’s first female president. She recently rebooted ...

Without a doubt, one of the hottest new startup accelerators in tech right now is Andreessen Horowitz’s Speedrun program. Launched in 2023, the accelerator has an acceptance rate of less than 1%. In a ...

Social Security, which provides benefits to about 70 million Americans, could run out of money sooner than expected, according to a new report from the Congressional Budget Office. The Old-Age and ...

Fullerton has launched its new city-operated ambulance transportation program. Under the model, fire personnel will manage the full emergency response, from initial patient contact to transport to a ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.